VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SPRO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SPROSpero Therapeutics, Inc.
$0.90$52M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
SPRO logo

Spero Therapeutics, Inc.

SPRO
NASDAQ · Vaccines & Infectious Disease
$0.90
At close - Nov 17, 4:00 PM EST - USD
Market Cap$52M
P/E-1.8x
52W High$3.08
Volume332.46K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Milestone Dependency Masks Underlying Clinical Pipeline Volatility

Spero Therapeutics faces a precarious financial outlook characterized by extreme revenue volatility, as evidenced by a 95.6% year-over-year revenue decline in 2026Q1.

GrowthMixed
ProfitabilityNegative
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

SPRO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-106% Peers

P/E is 106% below peer median

03

Market leadership

RS 16 · Lag

Laggard (Underperforming 84% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Nov 12

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
SPRO-61.65%
S&P 500 (^GSPC)+7.21%
1-Year Return
SPRO-62.91%
S&P 500 (^GSPC)+10.03%
3-Year Return
SPRO-24.26%
S&P 500 (^GSPC)+55.10%
5-Year Return
SPRO-94.40%
S&P 500 (^GSPC)+55.60%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-1.8x
Forward P/E
N/A
EV/EBITDA50th %ile
1.8x
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-1.8x
15.5x
0th· Low
EV/EBITDA
1.8x
11.3x
50th· Fair
Price/FCF
N/A
N/A
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$60M+24.3% YoY
Net income FY25
$9M+112.5% YoY
Free cash flow FY25
-$13M+46.2% YoY
Operating margin FY25
-0%+152.9 pts YoY
ROIC (FY25)-0.2%
Avg ROIC 5Y-85.2%
ROE (TTM)-75.2%
Piotroski Score5 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate6/12 (55%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Aug 12, 2026
-$0.16+5.9%
vs -$0.17
—
vs —
Q2 2026
May 13, 2026
-$0.13+27.8%
vs -$0.18
$258,000+0.0%
vs $258,000
Q2 2026
Mar 26, 2026
$0.53+365.0%
vs -$0.20
$41M+58.8%
vs $26M
Q4 2025
Nov 13, 2025
-$0.13+48.0%
vs -$0.25
$3M-74.6%
vs $12M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·6d ago
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update

SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) Cash and cash equivalents of $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

GlobeNewsWire·Nov 10, 2026
Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointment of William Ho, M.D.

GlobeNewsWire·Nov 4, 2026
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on November 2, 2026, of an aggregate of 217,000 restricted stock unit awards (RSUs) and 434,000 stock options to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero's new employee in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire·Nov 2, 2026
Spero Therapeutics to Present at Investor Conferences in November

CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a “fireside chat” at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company's leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors.

Filtered for Spero Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark SPRO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Spero Therapeutics, Inc. (SPRO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SPRO logoSPROSpero Therapeutics, Inc.Current
$0.90$52.19M-1.7824.27%-73.94%-75.22%—
VNDA logoVNDAVanda Pharmaceuticals Inc.
$3.81$229.12M-0.848.72%-119.87%-106.94%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.06$8.5B-24.77-100%—-29.41%—
AGEN logoAGENAgenus Inc.
$6.21$258.6M18.4110.37%20.98%——
IDYA logoIDYAIDEAYA Biosciences, Inc.
$27.40$2.41B-6.723024.43%-1149.62%-39.52%—
NKTR logoNKTRNektar Therapeutics
$35.91$1.23B-6.92-43.89%-339.67%-29.31%—

Compare SPRO vs Peers

Spero Therapeutics, Inc. (SPRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs VNDA

Most directly comparable listed peer for SPRO.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare SPRO against a more recognizable public peer.

Peer Set

Compare Top 5

vs VNDA, PRAX, AGEN, IDYA

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

SPRO SEC Filings & Documents

Spero Therapeutics, Inc. (SPRO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 12, 2026·SEC

Material company update

Nov 10, 2026·SEC

Material company update

Oct 27, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 26, 2026·SEC

FY 2025

Mar 27, 2025·SEC

FY 2024

Mar 13, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 12, 2026·SEC

FY 2026

Aug 12, 2026·SEC

FY 2026

May 13, 2026·SEC

Get notified when SPRO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SPRO Frequently Asked Questions

Spero Therapeutics, Inc. (SPRO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Spero Therapeutics, Inc.'s revenue?

Spero Therapeutics, Inc. (SPRO) reported $39.9M in revenue over the trailing twelve months. Revenue was $59.6M in fiscal year 2025.

How fast is Spero Therapeutics, Inc. growing?

Spero Therapeutics, Inc. (SPRO) grew revenue by 11.6% over the trailing twelve months, compared with the twelve months before.

Is SPRO profitable?

No. Spero Therapeutics, Inc. (SPRO) reported a net loss of $29.5M over the trailing twelve months.

Dividend & Returns
What is SPRO's return on equity?

Spero Therapeutics, Inc. (SPRO) had a return on equity (ROE) of -75.2% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Spero Therapeutics, Inc.'s free cash flow?

Spero Therapeutics, Inc. (SPRO) had negative free cash flow of $40.4M over the trailing twelve months.

What if you invested $1,000 in SPRO back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →